The Efficacy and Toxicity Profile of a Novel Panobinostat, Bortezomib and Dexamethasone Regime

Panobinostat, Bortezomib and Dexamethasone showed a PFS advantage compared with Bortezomib and Dexamethasone alone in the PANORAMA1 trial. Initial attempts to use this regimen in our patient group saw significant discontinuation rates due to poor tolerance, in particular grade 3-4 diarrhoea and neuropathy.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Randal Stronge, Matt Cross, Kevin Boyd Source Type: research